Great Lakes Clinical Trials Initiates Breakfast Cereal Study


Great Lakes Clinical Trials is looking for adult participants for a clinical trial to assess appetite levels after consuming two different breakfast meals.

Qualified participants must:

  • Be regular breakfast eaters, between 40-65 years of age

  • Not be lactose intolerant or allergic to wheat products

  • Not be substantially overweight or obese

  • Not be users of marijuana or any recreational drugs. A drug test will be administered at screening.

 The study involves:

  • One screening visit, lasting approximately 2 hours

  • Two testing days separated by 1 week, with each visit lasting approximately 5 hours in length.

Qualified participants will receive $90 for completing each testing day, up to $180 for the completing the entire study.

If you are interested in joining this trial, sign up by clicking here or visiting One of our staff will be in touch with you within 24 hrs to conduct a short phone screen to determine your eligibility. Otherwise, you can call our center directly at (773) 275- 3500 to speak with one of our staff today.

#AlwaysAndersonville: The Podcast – Steve Satek and Amber Holst of Great Lakes Clinical Trials

This week, Laura and Sara are joined by Steve Satek, President and Founder of Great Lakes Clinical Trials, and special guest, Great Lakes Director of Marketing, Amber Holst. Great Lakes specializes in the study of investigational medications, food products, devices and supplements for the treatment of chronic diseases, notably in Mental Health, Memory Disorders and Pain Management. Steve is one of the passionate, dedicated leaders in Alzheimer’s research and Great Lakes is determined to find a way to prevent the disease from occurring in aging older adults. With two locations in Arlington Heights and Chicago, you can find Great Lakes just around the corner at 5149 N. Ashland.

Click here to view this posting on the Andersonville Chamber of Commerce website:

(from left) Steve with Amber, Sara and Laura in Transistor’s Studio C.

(from left) Steve with Amber, Sara and Laura in Transistor’s Studio C.

Here are some references from Episode 34 you may want to check out:

  • Steve has been working in the field of clinical research for the last 25 years. His education is in biochemistry and molecular biology. He spent a good amount of time as bench researcher, but didn’t find it very social. What is a bench researcher? Check out this informative blog post.

  • Steve started working clinical trials for cancer treatments while working at Northwestern University, and he worked his way up to bigger trials for larger clinics. He soon discovered he preferred a smaller clinic setting, leading him to open Great Lakes Clinical Trials in 2014 in Andersonville.

  • Steve was recently named by Crain’s Chicago as one of the most notable LGBTQ Executives for 2018. Check out the full article here, and Steve’s feature here.

  • Great Lakes is servicing a growing community of older LGBTQ adults.

  • Steve has always wanted to bring a clinic to a community, as opposed to bringing a community to a clinic. The opening of Great Lakes Clinical Trials allowed Chicago’s north side population to have somewhere closer to travel to as one of only a few clinics in the Chicagoland area. Steve also mentions the close proximity to Swedish Covenant Hospital and the partnership of services provided there.

“We need medications to maintain general public health, and the only way to get them approved for prescription is through the clinical trial process.”
-Steve Satek

  • What is a clinical trial and how do people enroll? First, a team of board certified physicians assess each volunteer patient to make sure the individual qualifies for the trial. All of the trials at Great Lakes are free for the patient. View current studies here.

  • According to the Alzheimer’s Association, 5.7 million Americans are living with the disease. Steve has been doing Alzheimer’s research for nearly 20 years. There are only four medications approved by the FDA right now to treat memory loss, but none of them specifically target Alzheimers. Great Lakes is working to target the source of memory loss in the brain; not just treating the side effect of memory loss.

  • To get the word out about Great Lakes Clinical Trials, Steve and his team do informative workshops around Chicagoland to encourage participation in trials. View upcoming events here.

  • Steve has lived in Andersonville since 1991. He knows that active older adults in the neighborhood want to participate in research studies, and offering the convenience of a nearby clinic is invaluable.

Chicago Alzheimer’s Awareness Day will be celebrated on Thursday, November 8.

Chicago Alzheimer’s Awareness Day will be celebrated on Thursday, November 8.

Thursday, November 8 has been named Chicago’s Alzheimer’s Awareness Day by Mayoral Proclamation. Patients who have participated in past research studies will speak to help educate the community on why these type of studies are so important.  Special guests include both Alderman Osterman of the 48th Ward and Alderman O’Connor of the 40th Ward. Learn more about the event. RSVP for the event in advance.

  • The event will also feature free genetic cheek swabs to determine whether or not the Alzheimer’s gene is present, as well as memory screening. Individuals can also sign up for free memory screenings at any point at Great Lakes Clinical Trials.

  • Great Lakes is also conducting prevention trials with older adults, who may have the genetics to develop Alzheimer’s, but are not yet exhibiting systems. Prevention trials are for ages 60-70 and 70-75.

  • If given the chance to switch places with an Andersonville business for the day, Steve would choose to switch places with our very own Sara Dinges of the Andersonville Chamber of Commerce staff! Amber would choose to switch places with AlleyCat Comics (5304 N. Clark).

Purple ribbons line Clark Street in Andersonville in honor of November’s Alzheimer’s Awareness Month.

Purple ribbons line Clark Street in Andersonville in honor of November’s Alzheimer’s Awareness Month.

Visit Great Lakes Clinical Trials on these platforms:
Instagram: @greatlakesCT
Twitter: @greatlakesCT

Convenient On-line Booking for Memory Assessments

Great Lakes Clinical Trials is pleased to announce a new service for adults over 50 years of age: Online appointment booking for free memory assessments!


Beginning Monday, November 5th, visitors to the Great Lakes Clinical Trials website can now book their own Memory Assessment appointments from the convenience of their computer or smart device — without the need to call into our call center.

At each of these hour-long Memory Assessment appointments, you will meet with one of our trained memory experts, who will perform basic cognitive tests and discuss the results with you. For those between 60-75 years of age, we also provide free (optional) genetic testing for the ApolipoproteinE Alzheimer’s gene. Afterwards our team will also present clinical trial opportunities for which you may be qualified - though there is no obligation to join a study.

“We listened to the feedback from many of our current patients and developed this booking system to give greater control to users in scheduling their appointments,” commented Steve Satek, President of Great Lakes Clinical Trials. “For those who prefer to schedule their appointments over the phone, we will of course continue to offer that options through our main number at (773) 275-3500.”

Booking an appointment is easy as 1-2-3!

1.) Choose a location

Free genetic testing for the ApoE Alzheimer’s Gene, for those between 60-75 years of age

Free genetic testing for the ApoE Alzheimer’s Gene, for those between 60-75 years of age

Using this system, appointments can be booked at both our Chicago office located in the Andersonville neighborhood on the north side of the city, or at our Arlington Heights clinic located on the campus of the Lutheran Home,

2.) Choose your date and time.

Appointments can be booked every hour on the hour, between 8-4pm, Monday through Friday.

3.) Provide your name and contact information.

A confirmation of the appointment will be emailed to you or sent through text messaging.

Please feel free to pass this information along to your family and friends who may be interested in a free memory assessment.

Chicago Event to Encourage Participation in Alzheimer’s Clinical Research

Chicago Event to Encourage Participation in Alzheimer’s Clinical Research

On November 8th - Chicago Alzheimer's Awareness Day - Great Lakes Clinical Trials and the Global Alzheimer's Platform Foundation are hosting a major research recruitment event for people in the community who are interested in learning more about memory concerns and Alzheimer's disease.

Great Lakes Clinical Trials Initiates a Research Study for Individuals with Hidradenitis Suppurativa (HS)

Great Lakes Clinical Trials is currently enrolling participants for a research study of an investigational medication for the treatment of moderate to severe hidradenitis suppurativa.

What is HS?

Hidradenitis suppurativa (HS) is a long-term skin condition that features small, painful lumps under the skin. They typically develop where the skin rubs together, such as the armpits, the groin, between the buttocks and under the breasts. The lumps may break open and smell or cause tunnels under the skin.

What is this trial studying?

An investigational drug is being studied for patients who have moderate to severe hidradenitis suppurativa. The purpose of this study is to evaluate if the investigational drug works and determine its safety.

To qualify participants must:

  • Be over the age of 18

  • Have been diagnosed with hidradenitis suppurativa for at least one year

  • Have lesions in two distinct areas

  • Had had an inadequate response to an oral antibiotic for treatment of HS

Other entry criteria may apply and will be reviewed with you prior to participation.

What are my costs to participate in this trial?

You will receive all study-related care and study-related drug at no cost. For your participation, you will receive a stipend of $75 for each clinic visit you complete, up to $1,125 for completing the study.

How long with the trial last?

This trial will involve up to 15 visits to our clinic over approximately 1 year.

If you are interested in joining this trial, please complete our on-line survey by clicking here. One of our staff will then follow-up with you within 24 hrs. Otherwise, you can call our center directly at (773) 275-3500 to speak with one of our staff today.

Great Lakes Clinical Trials To Initiate Atopic Dermatitis (Eczema) Research Program

Great Lakes Clinical Trials is pleased to announce that we will soon be initiating a research program for individuals with Atopic Dermatitis. This is part of the company’s diversification into dermatology under the direction of our Board-Certified Dermatologist. Other dermatology research programs at Great Lakes Clinical Trials include studies in Psoriasis and Hidradenitis Suppurativa (HS).

If you would like our staff to contact you for enrollment, please fill out the form below to provide your contact information.

Name *
Phone Number *
Phone Number
Your Area(s) of Interest *

What is Atopic Dermatitis?

Atopic dermatitis is the most common type of eczema. More than 18 million American adults have atopic dermatitis. "Dermatitis" refers to a condition of the skin and "atopic" relates to diseases caused by allergic reactions.

During a flare, Atopic Dermatitis becomes a red, itchy rash which often appears on the cheeks, arms and legs. Many different physical and internal factors can trigger an eczema flare-up. The resulting inflammation causes increased blood flow and the urge to itch.

Eczema flares are part of the agonizing itch-scratch cycle. It’s hard to fight the physical and psychological components that drive the itch-scratch cycle. Scratching feels good at the time but can lead to more inflammation and even skin infections.

How is Atopic Dermatitis treated?

There’s no known cure for AD. Finding the right treatment is important to help reduce itching and discomfort. Calming the skin reduces stress and helps prevent excessive scratching that leads to skin infections.

Treatment options vary from over-the-counter skin care, prescription medication, and lifestyle changes. The best preventive measure is to moisturize the skin. This improves the function of the skin barrier. Healthier skin will become inflamed less often and provide a better barrier against allergens and irritants.

New Medications for Atopic Dermatitis

  • Dupilumab (Dupixent) was approved by the U.S. Food and Drug Administration (FDA) in March 2018. It is the first biologic agent approved to treat moderate to severe Atopic Dermatitis. Dupilumab is also in development for treating moderate to severe asthma. In two studies published in the New England Journal of Medicine, dupilumab improved the symptoms of AD compared with placebo. This included itchy skin (pruritus), anxiety and depression, and quality of life.

  • A recent phase II clinical trial evaluated an oral drug called baricitinib. In the trial, about 61 percent of patients with moderate to severe Atopic Dermatitis receiving baricitinib achieved a 50 percent or more reduction in the Eczema Area and Severity Index (EASI-50). This was compared to 37 percent of patients who received a placebo. Baricitinib is already approved by the FDA for rheumatoid arthritis.

  • Another study looked at a new treatment called nemolizumab in 216 adults with moderate-to-severe atopic dermatitis. All monthly doses of nemolizumab significantly improved pruritus in these patients during the course of the study.

  • In a 2015 study, 69 adults with Atopic Dermatitis were tested with a topical formulation of a drug called tofacitinib citrate. This drug is most often given orally to treat rheumatoid arthritis. It’s also used for psoriatic arthritis and ulcerative colitis. Tofacitinib citrate was shown to also have efficacy in people with Atopic Dermatitis. This was a very small study and more testing is needed. But the use of an RA medication in Atopic Dermatitis patients highlights some similarities. It suggests that Atopic Dermatitis functions more like an autoimmune disease than a surface-level skin disorder. More research to better understand these similarities should pave the way for new treatments.

Clinical Trials

Clinical trials are a great option for people looking to try a new treatment. If you’re interested in participating in clinical trial for AD, the National Eczema Association (NEA) posts a current list on their website. By participating in clinical trials, you can help shape the future of AD treatment options.

The Future of Atopic Dermatitis

It’s a promising time for AD research. There’s a public demand for more information, and researchers have taken an active interest in providing solutions. Based on current research and clinical studies, the outlook for AD patients is promising.

There are new medications and treatments on the horizon. Researchers are starting to treat AD like an autoimmune disease, which has opened a new realm of possibilities.

The statements provided above, along with additional information, can be found on a variety of Atopic Dermatitis informational websites, including: